HomePHS • FRA
add
Photocure ASA
Previous close
€4.22
Day range
€4.24 - €4.24
Year range
€4.01 - €6.13
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (NOK) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 145.45M | 0.78% |
Operating expense | 117.16M | -2.85% |
Net income | 12.33M | 186.06% |
Net profit margin | 8.48 | 183.61% |
Earnings per share | 0.45 | 181.25% |
EBITDA | 27.85M | 19.06% |
Effective tax rate | 23.70% | — |
Balance Sheet
Total assets
Total liabilities
| (NOK) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 266.99M | 3.11% |
Total assets | 713.58M | 0.99% |
Total liabilities | 213.92M | -10.51% |
Total equity | 499.66M | — |
Shares outstanding | 27.11M | — |
Price to book | 0.23 | — |
Return on assets | 7.23% | — |
Return on capital | 10.18% | — |
Cash Flow
Net change in cash
| (NOK) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 12.33M | 186.06% |
Cash from operations | 19.52M | -32.96% |
Cash from investing | 472.00K | 265.89% |
Cash from financing | -11.27M | 31.02% |
Net change in cash | 8.72M | -32.43% |
Free cash flow | 5.25M | -65.93% |
About
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Founded
1993
Website
Employees
102
